aiki - AIKI STOCK NEWS

AIkido Pharma Inc. (Nasdaq: AIKI) announced a Patent License Agreement for psilocybin technology aimed at cancer applications. This innovative technology is backed by four pending patent applications with the U.S. Patent and Trademark Office. Psilocybin, a psychedelic compound, has shown promise in alleviating cancer-related depression and anxiety, with research indicating lasting emotional benefits from single-dose treatments. CEO Anthony Hayes expressed enthusiasm for exploring psilocybin's potential in cancer treatment, which is an expanding area of interest.

AIkido Pharma Inc. (Nasdaq: AIKI) announced positive results from its Artificial Intelligence/Machine Learning research for pancreatic cancer. Pancreatic ductal adenocarcinoma (PDA) is the third leading cancer-related death cause in the US, with a low five-year survival rate of only 9%. AIkido's innovative approach involves screening drugs in primary cell culture and validating them in mouse models to discover effective treatments for early-stage PDA and post-surgical relapse prevention. The full article is available at Nature.com.

AIkido Pharma (NASDAQ: AIKI) held its Annual Meeting of Stockholders virtually on November 17, 2020. All proposals were approved, except for a proposed one-for-ten reverse stock split of the common stock. The meeting was adjourned to December 4, 2020, to allow more time for stockholders to consider the split. This reverse stock split is vital for raising stock prices to comply with Nasdaq's listing requirements, enhancing marketability to institutional investors. Top proxy advisory firms recommend a 'FOR' vote to maintain Nasdaq listing.

AIkido Pharma Inc. (Nasdaq: AIKI) announced the favorable publication of a peer-reviewed study revealing strong antiviral activity from newly licensed compounds against several viruses, including SARS-CoV2. Conducted with the University of Maryland, Baltimore, the study highlights the compounds' efficacy in inhibiting influenza, Ebola, MERS-CoV, and COVID-19. The technology is underpinned by patents filed with the U.S. Patent Office. CEO Anthony Hayes expressed optimism about these findings, emphasizing the platform's potential and encouraging shareholders to review the detailed article published in PNAS.

AIkido Pharma Inc. (Nasdaq: AIKI) announced progress on its next-generation chemotherapy drug DHA-dFdC, targeting pancreatic cancer. The company has successfully synthesized a key intermediate compound and is optimizing its solid lipid nanoparticle (SLN) delivery system. A new agreement with Parimer Scientific includes developing analytical methods and manufacturing processes for the drug. The 5-year survival rate for pancreatic cancer remains around 3%, underscoring the need for innovative treatments. The company aims to initiate preliminary biological testing soon.

AIkido Pharma Inc. (Nasdaq: AIKI) announced progress in its partnership with Cogia BioTech to enhance treatments for Pancreatic Ductal Adenocarcinoma (PDA). Key updates include the identification of genetic markers, development of tools for personalized medicine, and survival associations for PDA targets. CEO Anthony Hayes expressed satisfaction with Cogia's advancements, which utilize AI and machine learning to improve diagnostics. AIkido is committed to expanding its therapeutic pipeline in oncology and developing antiviral platforms against various viruses.

AIkido Pharma Inc. (Nasdaq: AIKI) will present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, 2020. Vice President Darrell Dotson will outline the Company’s business during a live presentation on September 15 at 3:00 p.m. ET. The conference is virtual, and institutional investors can register online. AIkido specializes in biotechnology with a focus on anti-cancer therapeutics and antiviral platforms.

AIkido Pharma Inc. (Nasdaq: AIKI) announced positive results from a peer-reviewed study published in the Journal of Virology. The study found that 17 out of 20 FDA-approved drugs inhibit SARS-CoV-2 at non-cytotoxic concentrations, suggesting potential pan-anti-coronaviral activity. CEO Anthony Hayes highlighted this as validation of the antiviral technology optioned from the University of Maryland, Baltimore. The company has also secured a Master License Agreement for antiviral compounds targeting various viruses, and two patent applications are filed with the USPTO.

AIkido Pharma Inc. (Nasdaq: AIKI) announced funding for a 30-day survival study in mice at the University of Kentucky, related to the anticancer drug G4-1, a novel proteasome inhibitor. In exchange for the funding, AIkido receives an exclusive option to license the drug, contingent on study results. The Option includes two patents expiring in the mid-2030s. CEO Anthony Hayes highlighted promising preliminary data for G4-1 compared to existing drugs, anticipating positive study results to enhance their oncology portfolio.